INTRODUCTION {#s1}
============

*Clostridioides difficile* infections (CDI) are the leading cause of healthcare-associated infections in the United States and are associated with significant morbidity \[[@CIT0001], [@CIT0002]\]. Historically, both oral metronidazole and oral vancomycin were commonly used for the treatment of nonsevere CDI. As of 2018, the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) recommend vancomycin over metronidazole as the first-line treatment for nonsevere CDI in adults \[[@CIT0003]\]. This is a strong recommendation based primarily on the results of 2 randomized controlled trials \[[@CIT0004], [@CIT0005]\], in which findings were driven mostly by severe CDI cases, as well as the findings of an observational study that focused on mild to moderate CDI cases \[[@CIT0006]\]. Others have shown that the median duration of CDI symptoms is shorter with vancomycin compared to metronidazole \[[@CIT0007], [@CIT0008]\].

Studies evaluating the relative efficacy of metronidazole versus vancomycin for nonsevere CDI in children are lacking. Because of the scarcity of evidence addressing this question in the pediatric population, the IDSA/SHEA guidelines recommend oral metronidazole as a weak recommendation with a low quality of evidence for children with nonsevere CDI, specifically stating, "Either metronidazole or vancomycin is recommended for the treatment of children with an initial episode or first recurrence of nonsevere CDI." \[[@CIT0003]\] Though data for the management of children with severe or fulminant CDI also are limited, experts agree because of the significant risk of poor outcomes and the strength of the evidence supporting oral vancomycin in the adult population that oral vancomycin should be used as first line therapy for both children and adults with severe or fulminant CDI.

A concern that has been raised frequently with the use of oral vancomycin for CDI therapy is the association with the subsequent emergence of vancomycin-resistant enterococci (VRE) \[[@CIT0007]\]; however, this has not been consistently demonstrated in the published literature. The most robust study to date, including patients diagnosed with CDI at more than 1200 Veterans Affairs hospitals and clinics, suggests the risk of isolating VRE from a clinical culture within the subsequent 3 months is similar for the 2 agents \[[@CIT0009]\]. Our objective was to compare the clinical outcomes of hospitalized children with nonsevere CDI treated with oral metronidazole versus oral vancomycin using a multicenter, observational cohort.

METHODS {#s2}
=======

Study Setting and Design {#s3}
------------------------

This study included patients under 18 years of age hospitalized at The Johns Hopkins Hospital, Bayview Medical Center, or Howard County General Hospital with nonsevere CDI between January 2012 and December 2018. As there is no validated definition for nonsevere CDI in children, the adult criteria (developed by expert opinion \[[@CIT0003]\]) of peripheral white blood cell count \<15 000 cells/mm^3^ and a serum creatinine level of \<1.5 mg/dL in addition to no hypotension, ileus, or megacolon, and not requiring intensive care unit care was used to define nonsevere CDI.

The clinical microbiology laboratory provided the investigators with a list of all children with a positive stool nucleic acid amplification test (NAAT) for *C. difficile* toxin B during the study period. The microbiology laboratory routinely rejects samples for CDI testing from children (1) with formed stool, (2) who had previous CDI testing within 7 days, or (3) who received a laxative within 48 hours. Infectious diseases consultation is recommended for any child under 2 years of age for whom CDI testing is requested.

Manual chart review was conducted for all children with a positive *C. difficile* NAAT to identify those meeting eligibility criteria. The Epic Care Everywhere network that includes inpatient and outpatient records from a large number of healthcare facilities in the United States was reviewed for all patients to identify relevant pre- and post-discharge data. Similarly, the Chesapeake Regional Information System for Our Patients (CRISP), which includes inpatient, outpatient, and emergency department information for children in the state of Maryland and the District of Columbia, also was reviewed. This study was approved by The Johns Hopkins University School of Medicine Institutional Review Board with a waiver of informed consent.

All of the following criteria had to be present for children with positive CDI testing for inclusion in the study: (1) at least 3 new-onset unformed stools within a 24 hour period; (2) at least 2 years of age and under 18 years of age; (3) hospitalization for at least 48 hours for CDI; (4) no laxative use within the previous 48 hours; (5) no plausible alternate explanation for diarrhea (as determined by adjudication by both a gastroenterologist (J.W.) and an infectious diseases physician (P.D.T.); (6) receipt of either oral metronidazole or oral vancomycin therapy (as explained in more detail below); (7) no previous episode of CDI within the past 3 months \[[@CIT0016]\] (children who had a nonsevere episode of CDI more than 3 months prior to the current episode with complete resolution of symptoms were included); (8) no concurrent non-CDI--targeted antibiotic therapy while receiving CDI treatment; and (9) not meeting criteria for severe or fulminant CDI.

Exposures and Outcomes {#s4}
----------------------

The primary exposure was receipt of oral metronidazole therapy. To be eligible for the oral metronidazole group, patients had to receive oral metronidazole from day 1 of treatment and for at least 5 days. Patients initially prescribed oral vancomycin who were converted to oral metronidazole within the first 48 hours of antibiotic therapy (and remained on metronidazole for the duration of therapy) also were designated to the exposed group. Unexposed patients were those prescribed oral vancomycin as initial therapy for the duration of therapy. As with the exposed group, patients transitioned from oral metronidazole to oral vancomycin within 48 hours of the initiation of CDI-targeted therapy were included in the unexposed group. Any patient receiving oral metronidazole or oral vancomycin and transitioned to the alternate treatment after 48 hours were excluded from further analysis. Furthermore, any child who received vancomycin as a tapered and pulsed regimen also were excluded.

The primary outcome was documented resolution or improvement of diarrhea (by the treating clinician) within 5 days of antibiotic treatment initiation. For patients discharged prior to day 5 with no post-discharge records available (after evaluating the medical chart, Epic Care Everywhere, and CRISP) an assumption was made that resolution or improvement of diarrhea occurred by day 5.

Recurrence of disease, defined as occurrence of another episode of CDI following resolution of the previous episode of CDI, within a 12-week period was a secondary outcome. To be considered a recurrent episode, the same clinical and laboratory criteria as the initial CDI episode was necessary. Additionally, incident VRE isolation from clinical cultures within 12 weeks after the initiation of treatment for CDI was collected for both groups.

Demographic, pre-existing medical conditions, microbiology, treatment, and outcomes data were manually collected and entered into a secure REDCap database. Surveillance case definitions included the following: community-onset (symptoms within 3 days of admission and no previous admission within the past 28 days), facility-associated community-onset healthcare (history of hospital admission in the past 28 days), and healthcare facility-onset (onset greater than 3 days after admission) \[[@CIT0017]\].

Statistical Analysis {#s5}
--------------------

Using multivariable logistic regression, propensity scores were calculated for each patient with the dependent variable being metronidazole therapy. Covariates used for generating propensity scores included: previous episode of CDI (ie, nonsevere episode of CDI more than 3 months prior to the current episode with complete resolution of symptoms), chemotherapy within the previous 6 months, hematologic stem-cell transplantation (HSCT) within the previous 12 months, solid organ transplant recipient, ulcerative colitis, Crohn's disease, and surveillance case definitions of CDI.

Patients who received metronidazole treatment were weighted by the inverse of the propensity score and patients who received oral vancomycin were weighted by the inverse of 1 minus the propensity score. A new weighted pseudo-population was created to ensure improved balance of baseline characteristics between the groups. Individuals who received an "unexpected" antibiotic (ie, received oral vancomycin when the propensity score suggested the patient would be more likely to receive oral metronidazole) based on their baseline characteristics were given an increased weight and individuals who received the "expected" antibiotic were assigned a decreased weight as they already were represented adequately in the study population. Weighted *t* test or χ ^2^ tests were used to compare baseline characteristics after inverse probability of treatment weighting was applied. Stabilized weights were used to reduce the influence of extreme weights. Standardized differences---that describe the between-group differences in standard deviation units---also were used to assess balance, with values less than 10% considered appropriately balanced. In the final analysis, weighted logistic regression was used to estimate odds ratios and 95% confidence intervals (CI) for the outcome, adjusting for variables with standardized differences greater than 10%. A 2-sided *P* value \<.05 was considered statistically significant for all tests. Statistical analysis was completed using STATA version 13.0 (StataCorp, College Station, TX).

RESULTS {#s6}
=======

There were 273 hospitalized children with a positive *C. difficile* NAAT for the toxin B gene identified between January 2012 and December 2018 ([Figure 1](#F1){ref-type="fig"}). A total of 192 patients met eligibility criteria, of which 141 (73.4%) received oral metronidazole and 51 (26.6%) children received oral vancomycin. As shown in [Table 1](#T1){ref-type="table"}, there was no significant difference in demographics, pre-existing medical conditions, including immunocompromised status or underlying inflammatory bowel disease (IBD) or surveillance categories between children in the metronidazole group and the vancomycin group. However, children in the vancomycin group had a higher likelihood of having a previous CDI episode within 2 years of the current episode 9.9% versus 29.4%.

###### 

Comparison of Baseline Characteristics of 192 Hospitalized Children With Mild to Moderate *Clostridioides difficile* Infection Treated With Oral Metronidazole Versus Oral Vancomycin in the Full Cohort and Propensity-Score Weighted Cohort

                                                                                           Full Cohort       Weighted Cohort^^a^^                                                              
  ---------------------------------------------------------------------------------------- ----------------- ---------------------- ------ -------- ----------------- ----------------- ------ --------
  Age, median (interquartile range)                                                        8 years (4--13)   9 years (4--15)        .242   0.188    8 years (8--13)   9 years (4--15)   .212   0.215
  Male, n (%)                                                                              76 (53.9)         27 (52.9)              .906   0.019    77 (54.1)         26 (51.2)         .740   0.058
  Race/ethnicity, n (%)                                                                                                                                                                        
   Black                                                                                   36 (25.5)         11 (21.6)              .573   -0.093   35 (24.6)         11 (20.9)         .614   -0.087
   White                                                                                   77 (54.6)         35 (68.6)              .082   0.289    81 (56.9)         34 (68.0)         .191   0.231
   Latino                                                                                  7 (5.0)           2 (3.9)                .763   -0.050   6 (4.4)           2 (3.5)           .783   -0.045
   Asian                                                                                   8 (5.7)           0                      .082   -0.346   8 (5.7)           0                 .094   -0.347
   Other                                                                                   13 (9.2)          3 (5.9)                .460   -0.126   12 (8.5)          4 (7.5)           .855   -0.034
  Previous episode of *Clostridioides difficile* infection within past 2 years, n (%)^b^   14 (9.9)          15 (29.4)              .001   0.502    23 (15.9)         8 (16.1)          .967   0.006
  Pre-existing medical conditions, n (%)                                                                                                                                                       
   Chemotherapy within the past 6 months                                                   29 (20.6)         6 (11.8)               .163   -0.239   25 (17.9)         8 (16.2)          .823   -0.043
   Hematopoietic stem cell transplant in past 12 months                                    15 (10.6)         5 (9.8)                .867   -0.027   15 (10.2)         5 (10.5)          .955   0.010
   Solid organ transplant recipient                                                        8 (5.7)           3 (5.9)                .956   0.009    8 (5.7)           3 (5.3)           .917   -0.018
   Crohn's disease                                                                         10 (7.1)          5 (9.8)                .536   0.097    11 (8.0)          4 (8.1)           .989   0.002
   Ulcerative colitis                                                                      8 (5.7)           6 (11.7)               .152   0.215    11 (7.8)          4 (8.0)           .970   0.006
  Surveillance categories^c^                                                                                                                                                                   
   Community-onset                                                                         35 (24.8)         18 (35.3)              .152   0.228    41 (28.6)         15 (30.4)         .813   0.040
   Community-onset healthcare, facility-associated                                         48 (34.0)         15 (29.4)              .546   -0.099   45 (31.9)         15 (30.0)         .817   -0.041
   Healthcare facility-onset                                                               58 (41.1)         18 (35.3)              .465   -0.120   56 (39.5)         20 (39.6)         .993   0.001

^a^Weighted cohort numbers rounded to whole numbers.

^b^Children who experienced a previous *Clostridioides difficile* infection episode within the past 3 months were excluded.

^c^ [www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf](www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf).
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In the weighted propensity-score cohort, 101 of 141 (71.7%) children with nonsevere CDI receiving oral metronidazole had clinical improvement by day 5, whereas 44 of 51 (86.3%) cases resolved with oral vancomycin treatment. The odds of clinical resolution were lower in the metronidazole group than in the vancomycin group (odds ratio \[OR\], 0.40; 95% CI, 0.17--0.97; *P* = .04), after additional adjustment for variables with standard biases greater than 0.10. Among the 40 children not experiencing clinical resolution by day 5 of initial oral metronidazole, 20 (50%) of these children were changed to oral vancomycin. The median duration of CDI treatment was 10 days (interquartile range \[IQR\] 10--13 versus IQR 10--12) in both treatment arms (*P* = .98).

Limiting the evaluation to children with resolution of symptoms by day 5, recurrence of disease within 12 weeks following complete resolution of the prior CDI episode was observed in 22 of 101 (21.7%) children treated with metronidazole and 7 of 44 (15.9%) children treated with oral vancomycin. The overall odds of CDI recurrence within 12 weeks were similar between the metronidazole and vanocmycin groups (OR, 1.47; 95% CI, 0.58--3.75; *P* = .42). There were 6 incident episodes of VRE isolated from clinical cultures in the 192 children meeting eligibility criteria: 4 (2.8%) in the metronidazole arm and 2 (3.9%) in the vancomycin arm, *P* = .43.

DISCUSSION {#s7}
==========

In this multicenter, observational, propensity-score--weighted cohort of 192 children with nonsevere CDI, patients receiving vancomycin were more likely to experience clinical resolution by day 5 compared with those receiving metronidazole. The odds of recurrent CDI within 12 weeks were similar between the 2 groups. Consistent with data from adult patients \[[@CIT0006], [@CIT0018]\], our findings suggest that vancomycin may have more favorable clinical efficacy than metronidazole for children with nonsevere CDI. To our knowledge, this is the first comparative effectiveness study of metronidazole and vancomycin for children hospitalized with nonsevere CDI.

Metronidazole has been traditionally prescribed for both children and adults as the first-line treatment for CDI due to its reported clinical efficacy, lower cost, and perceived reduced risk of adverse events, including subsequent VRE colonization, compared to oral vancomycin \[[@CIT0003]\]. This practice was supported by initial small-scale randomized controlled trials (RCTs) in adults, which suggested that metronidazole and vancomycin were equivalent for the treatment of CDI \[[@CIT0019], [@CIT0020]\]. Recent RCTs studies have refuted these findings, particularly for patients with severe CDI \[[@CIT0004], [@CIT0005]\]. Although the measurable impact of oral vancomycin being associated with improved outcomes compared to oral metronidazole for nonsevere CDI has not been apparent across all studies that have attempted to address this question \[[@CIT0004], [@CIT0021]\], *no studies* have demonstrated improved clinical outcomes with the use of metronidazole. Interventional studies comparing oral metronidazole and oral vancomycin for nonsevere CDI do not exist in the pediatric population. Although some observational studies have attempted to explore this question, insufficient sample sizes have precluded its adequate investigation \[[@CIT0022], [@CIT0023]\].

There are several possible explanations for the apparent improved effectiveness of vancomycin compared to metronidazole for the treatment of CDI. Some studies have suggested that metronidazole minimum inhibitory concentrations against *C. difficile* are rising, although vancomycin resistance remains rare \[[@CIT0024]\]. The reduced effectiveness of oral metronidazole may be compounded by the differential absorption and fecal concentrations of the 2 agents. Vancomycin is poorly absorbed, which results in high fecal concentrations after oral administration \[[@CIT0028]\]. In contrast, metronidazole is very well absorbed; only 6--15% is excreted in stool \[[@CIT0029]\].

An important consideration with the use of oral vancomycin is the cost of vancomycin capsules---even when generic \[[@CIT0030]\]. For hospitalized patients, as a cost-containment measure, inpatient pharmacies often compound an oral solution from intravenous vancomycin \[[@CIT0031]\], but this can prove challenging for outpatients or for patients at the time of hospital discharge if the duration of the outpatient treatment course is not provided by the inpatient pharmacy. Ideally, with the publication of the most recent CDI guidelines \[[@CIT0003]\], both the cost and barriers associated with the inconsistent coverage of oral vancomycin by insurance coverage will be reduced. In the meantime, it is incumbent upon clinicians to weigh the costs of oral vancomycin---particularly for outpatients---into their decision making.

Approximately 15% of our cohort consisted of children with IBD, with equal distribution in both treatment groups. The small numbers of patients with IBD limited a meaningful subgroup analysis of this population. Differentiating IBD exacerbations from CDI remains challenging due to the overlapping clinical presentations of the 2 conditions. To complicate matters, patients with IBD are at an increased risk for CDI. Inflammatory bowel disease is associated with a 4.8-fold increased risk of CDI compared to the absence of IBD, with no differences observed between ulcerative colitis and Crohn's disease \[[@CIT0032]\]. Unique underlying IBD-related risk factors include the use of chronic immunosuppression, frequent healthcare exposures, and an ongoing inflammatory state, which disrupts the normal intestinal symbiotic state \[[@CIT0033]\]. Ultimately, we included patients with IBD if we were in agreement with the treating gastroenterologist that more likely than not the presenting symptoms seemed consistent with CDI and warranted CDI-targeted therapy. We realize some misclassification still may have occurred; however, when taking into consideration real-world clinical decision making for patients with IBD, we believe the practical constraints in confidently assigning a diagnosis of CDI should not prohibit them from inclusion in comparative effectiveness studies for the management of CDI.

This study has several limitations. First, only 192 children were included. We deliberately imposed a strict eligibility criteria---including the need for hospitalization---even though in reality the majority of patients with nonsevere CDI are not hospitalized \[[@CIT0013]\]. We did so understanding that this would compromise the sample size of our population but would increase the validity of our findings. Second, although this study involved 3 hospitals, all 3 hospitals are located within the same geographic region, have a central laboratory, and share the same local CDI diagnosis and treatment guidelines. Further studies are needed to verify the generalizability of our findings across regions where the epidemiology of *C. difficile* ribotypes and general clinical management practices may differ. Third, this is a retrospective observational study. In addition to institutional electronic medical records, the Epic Care Everywhere and CRISP databases were accessed to identify relevant healthcare encounters before and after discharge, but the possibility of missing data remains. In the absence of records to suggest treatment failure, we assumed clinical resolution. As a result, the proportions of clinical resolution may have been overestimated, although there is no reason to suspect that missing data would have had a greater impact on 1 treatment group compared with the other. Fourth, we used propensity score inverse probability of treatment weighting to address imbalances in measured confounders. Because patients were not randomized to treatment, the possibility of unmeasured confounding remains. Finally, this study used the IDSA/SHEA definitions to stratify disease severity \[[@CIT0003]\]. These definitions were developed for adult patients and may not be able to accurately identify children with severe disease, potentially leading to some misclassification. However, available data suggest that these definitions likely "overcall" severe CDI in children \[[@CIT0034], [@CIT0035]\] and therefore is unlikely to have impacted our results.

All limitations notwithstanding, our study suggests that children hospitalized with nonsevere CDI have earlier resolution of clinical findings when prescribed oral vancomycin compared with oral metronidazole. Larger interventional studies are necessary to evaluate the reproducibility of our findings.
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